14,000 Shares in Cellebrite DI Ltd. $CLBT Bought by Venturi Wealth Management LLC

Key Points

• Venturi Wealth Management LLC acquired 14,000 shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the 2nd quarter, totaling approximately $224,000.
• Cellebrite DI reported 0.12 earnings per share for the last quarter, exceeding expectations, with a year-over-year revenue increase of 18.4%.
• Analyst ratings for Cellebrite DI remain mixed, with four analysts providing a Buy rating and one rating it as a Sell, while the consensus target price is $21.75.

Venturi Wealth Management LLC bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 14,000 shares of the company's stock, valued at approximately $224,000.

Several other large investors have also made changes to their positions in the company. OneDigital Investment Advisors LLC raised its position in shares of Cellebrite DI by 2.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after buying an additional 688 shares during the period. Signaturefd LLC raised its position in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company's stock worth $32,000 after buying an additional 819 shares during the period. Bosun Asset Management LLC raised its position in shares of Cellebrite DI by 2.5% in the 1st quarter. Bosun Asset Management LLC now owns 44,376 shares of the company's stock worth $862,000 after buying an additional 1,069 shares during the period. Advisors Asset Management Inc. raised its position in shares of Cellebrite DI by 24.7% in the 1st quarter. Advisors Asset Management Inc. now owns 6,133 shares of the company's stock worth $119,000 after buying an additional 1,214 shares during the period. Finally, Assetmark Inc. acquired a new stake in Cellebrite DI in the 1st quarter valued at $33,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $19.10 on Friday. The business has a 50-day moving average of $16.71 and a 200-day moving average of $16.94. The company has a market capitalization of $4.57 billion, a PE ratio of -25.13, a P/E/G ratio of 3.47 and a beta of 1.29. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. During the same period last year, the firm earned $0.10 earnings per share. The company's revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on CLBT. Wall Street Zen upgraded Cellebrite DI from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Needham & Company LLC lowered their price target on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Cellebrite DI in a report on Wednesday. JPMorgan Chase & Co. increased their price target on Cellebrite DI from $20.00 to $23.00 and gave the company an "overweight" rating in a report on Wednesday, September 24th. Finally, Lake Street Capital lowered their price target on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cellebrite DI has a consensus rating of "Moderate Buy" and an average target price of $21.75.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.